Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | Brentuximab vedotin plus ICE as a second line treatment in R/R Hodgkin lymphoma

Ryan Lynch, MD, Seattle Cancer Care Alliance, University of Washington, Seattle, WA, discusses the results of the Phase I/II study (NCT02227199) aiming to improve post-autologous stem cell transplant (ASCT) results with brentuximab vedotin (BV) and ICE (ifosfamide, carboplatin and etoposide) therapy in relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) patients. While many patients experienced mild adverse events, the overall safety profile was deemed acceptable. Findings suggest that BV-ICE has potential as a salvage regimen for R/R cHL patients, especially when administered prior to ASCT. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Disclosures

Ryan Lynch, MD, has received research funding from TG Therapeutics, Takeda, Incyte, Rhizen Pharmaceuticals, Bayer, Cyteir, and Genentech, and has done consultancy for MorphoSys.